Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center

• Published in: Journal for immunotherapy of cancer Vol. 10; no. 4; p. e004149
• Main Authors: Rosenbaum, Evan, Antonescu, Cristina R, Smith, Shaleigh, Bradic, Martina, Kashani, Daniel, Richards, Allison L, Donoghue, Mark, Kelly, Ciara M, Nacev, Benjamin, Chan, Jason E, Chi, Ping, Dickson, Mark A, Keohan, Mary L, Gounder, Mrinal M, Movva, Sujana, Avutu, Viswatej, Thornton, Katherine, Zehir, Ahmet, Bowman, Anita S, Singer, Samuel, Tap, William, D’Angelo, Sandra
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.04.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Antibodies; Antineoplastic Agents, Immunological - pharmacology; Antineoplastic Agents, Immunological - therapeutic use; Biomarkers; Biomarkers, Tumor; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Clinical trials; Cloning; Genomes; Genomics; Hemangiosarcoma - drug therapy; Hemangiosarcoma - genetics; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Immunotherapy Biomarkers; Laboratories; Lung Neoplasms - drug therapy; Lymphedema; Lymphocytes; Metastasis; Mutation; Patients; Quality control; Radiation; Retrospective Studies; Sarcoma; Signatures; Software; Transcriptome; Sarcoma; Biomarkers, Tumor; Immunotherapy

BackgroundAngiosarcoma is a histologically and molecularly heterogeneous vascular neoplasm with aggressive clinical behavior. Emerging data suggests that immune checkpoint blockade (ICB) is efficacious against some angiosarcomas, particularly cutaneous angiosarcoma of the head and neck (CHN).Methods...